We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Tennessee Devicemaker Cited for Risk Analysis, Labeling

Tennessee Devicemaker Cited for Risk Analysis, Labeling

July 27, 2018

The FDA hit Nashville-based CNMC Company with a Form 483 over inadequate risk analysis and device labeling procedures observed by an agency investigator during a March inspection.

The firm’s procedures for controlling and inspecting device labeling did not document label release. The facility did not document any label inspections or releases for its EquiDose II Diode Detector dose monitors.

The company performed an incomplete risk analysis for its Model 206 Electrometer device, failing to address possible hazards related to functional failures, energy and maintenance. The analysis did not fully address potential environmental hazards, such as using the device outside its intended environment, or possible usage related hazards, such as usage by untrained personnel or inadequate labeling.

In addition, the device’s hazard of incorrect measurement is considered negligible “although resulting measurements may have a direct relationship to the accuracy of the radiation therapy dose delivered,” the agency said.

The firm also failed to analyze service reports to identify and predict quality issues. Between January 2017 and February 2018, it did not analyze receiving and service records that it initiated. Some service reports were missing required information, such as the date of service, the test and inspection data and the personnel servicing the device.

The investigator cited the firm’s failure to document the results of corrective and preventive actions. Out of seven closed CAPA request forms that were initiated since January 2016, five had no documentation of the results of planned corrective actions and they all lacked documentation of the results of proposed verification activities.

In another observation, the agency official noted that the firm’s rework and reevaluation activities were not fully recorded in the device history record. Specifically, the firm did not document the details of rework performed on a Model 206 feedback module assembly. The nature of the rework performed should have been documented on a product rework record and an engineer needed to approve it first.

The device history record contained no documentation of the type of rework and/or repair activities performed, or any engineering approval of repairs, the agency said.

View today's stories

Devices Inspections and Audits

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 26Apr

    Building the Foundation for QMS AI

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Final Order Requires PMA for Spinal Spheres

  • FDA and Lupus Research Alliance Form Drug Development Consortium

  • GSK and Scynexis Ink Antifungal Licensing Deal Drug

  • FDA Clears Bot Image’s AI Software for Prostate Cancer Screening

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing